Literature DB >> 24292671

An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation.

J Wolf1, K Müller-Decker2, C Flechtenmacher3, F Zhang4, M Shahmoradgoli4, G B Mills4, J D Hoheisel1, M Boettcher1.   

Abstract

The gold standard for determining the tumorigenic potential of human cancer cells is a xenotransplantation into immunodeficient mice. Higher tumorigenicity of cells is associated with earlier tumor onset. Here, we used xenotransplantation to assess the tumorigenic potential of human breast cancer cells following RNA interference-mediated inhibition of over 5000 genes. We identify 16 candidate tumor suppressors, one of which is the zinc-finger transcription factor SALL1. Analyzing this particular molecule in more detail, we show that inhibition of SALL1 correlates with reduced levels of CDH1, an important contributor to epithelial-to-mesenchymal transition. Furthermore, SALL1 expression led to an increased migration and more than twice as many cells expressing a cancer stem cell signature. Also, SALL1 expression correlates with the survival of breast cancer patients. These findings cast new light on a gene that has previously been described to be relevant during embryogenesis, but not carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24292671      PMCID: PMC6662585          DOI: 10.1038/onc.2013.515

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

1.  An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.

Authors:  Casey W Shuptrine; Reham Ajina; Elana J Fertig; Sandra A Jablonski; H Kim Lyerly; Zachary C Hartman; Louis M Weiner
Journal:  Cancer Immunol Immunother       Date:  2017-08-02       Impact factor: 6.968

Review 2.  Mutual interaction between BCL6 and miRNAs contributing to the pathogenesis of various cancers.

Authors:  Z Wei; W Gao; Y Wu; B Ni; Y Tian
Journal:  Clin Transl Oncol       Date:  2015-06-25       Impact factor: 3.405

3.  An In Vivo Gain-of-Function Screen Identifies the Williams-Beuren Syndrome Gene GTF2IRD1 as a Mammary Tumor Promoter.

Authors:  Yongliang Huo; Timothy Su; Qiuyin Cai; Ian G Macara
Journal:  Cell Rep       Date:  2016-05-26       Impact factor: 9.423

4.  In vivo shRNA screens in solid tumors.

Authors:  Gaetano Gargiulo; Michela Serresi; Matteo Cesaroni; Danielle Hulsman; Maarten van Lohuizen
Journal:  Nat Protoc       Date:  2014-11-20       Impact factor: 13.491

5.  In Vivo Genome-Wide Pooled RNAi Screens in Cancer Cells to Identify Determinants of Chemotherapy/Drug Response.

Authors:  Margaret L Dahn; Paola Marcato
Journal:  Methods Mol Biol       Date:  2021

Review 6.  The nucleosome remodeling and deacetylase complex in development and disease.

Authors:  Jeannine Basta; Michael Rauchman
Journal:  Transl Res       Date:  2014-05-10       Impact factor: 7.012

7.  Detection of epigenetic field defects using a weighted epigenetic distance-based method.

Authors:  Ya Wang; Min Qian; Peifeng Ruan; Andrew E Teschendorff; Shuang Wang
Journal:  Nucleic Acids Res       Date:  2019-01-10       Impact factor: 16.971

8.  SALL1 functions as a tumor suppressor in breast cancer by regulating cancer cell senescence and metastasis through the NuRD complex.

Authors:  Chunling Ma; Fang Wang; Bing Han; Xiaoli Zhong; Fusheng Si; Jian Ye; Eddy C Hsueh; Lynn Robbins; Susan M Kiefer; Yanping Zhang; Pamela Hunborg; Mark A Varvares; Michael Rauchman; Guangyong Peng
Journal:  Mol Cancer       Date:  2018-04-06       Impact factor: 27.401

9.  RNAi screens identify CHD4 as an essential gene in breast cancer growth.

Authors:  Carolina D'Alesio; Simona Punzi; Angelo Cicalese; Lorenzo Fornasari; Laura Furia; Laura Riva; Alessandro Carugo; Giuseppe Curigliano; Carmen Criscitiello; Giancarlo Pruneri; Pier Giuseppe Pelicci; Mario Faretta; Daniela Bossi; Luisa Lanfrancone
Journal:  Oncotarget       Date:  2016-12-06

10.  Epigenetic modification of SALL1 as a novel biomarker for the prognosis of early stage head and neck cancer.

Authors:  Kiyoshi Misawa; Yuki Misawa; Atsushi Imai; Daiki Mochizuki; Shiori Endo; Masato Mima; Ryuji Ishikawa; Hideya Kawasaki; Takashi Yamatodani; Takeharu Kanazawa
Journal:  J Cancer       Date:  2018-02-28       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.